Terms of use

…to receive electronic communications from CytomX (via a posting on the Services), and you agree that any such communications satisfy any legal requirement to make such communications in writing. You…

Read More

test title

test block…

Read More

Praluzatamab Ravtansine, a CD166-Targeting Antibody– Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Boni V, Fidler MJ, Arkenau HT, et al. Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial [published online ahead of print,…

Read More

CytomX Privacy Notice

…may provide to us through your use of our website located at www.CytomX.com, our social media pages, and any of our other web pages that link to this Privacy Notice…

Read More

CX-072 (pacmilimab), a Probody®️ PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

Naing A, Thistlethwaite F, De Vries EG, et al. Journal for ImmunoTherapy of Cancer 2021;9:e002447. doi: 10.1136/jitc-2021-002447…

Read More

Job listings

…by CytomX or CytomX employees may come from similar sounding emails with endings like “@cytomxjobs.com” or “@cytomxtx.com” or even emails ending in common public domain addresses with endings like “@gmail.com,”…

Read More

Privacy policy

…information related to the CytomX website currently located at http://cytomx2018.wpengine.com/ (the “Website,” and together with any successor URLs, applications and other online services CytomX may offer, the “Services”). By accessing…

Read More